Frontier Biotech announced that Qihe Frontier Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a Frontier Biotech Notice from the State Drug Administration. Qihe Frontier Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for loxoprofen sodium patches issued by the State Drug Administration to approve the production of the drug. The drug is registered as a chemical class of 4, with specifications of 14cm x 10cm and 7cm x 10cm. It is used for anti-inflammatory and analgesic pain due to osteoarthritis, muscle pain, and swelling or pain caused by trauma. The “Drug Registration Certificate” for loxoprofen sodium patch approves the production of this drug. The drug is registered and classified into 4 categories of chemicals, with specifications of 14cm x 10cm and 7cm x 10cm. It is used for anti-inflammatory and analgesic effects of swelling or pain caused by osteoarthritis, muscle pain, and trauma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.